The diabetes map of thuringia - A project for the continuous evaluation and for the improvement of treatment quality in the primary care of patients with diabetes meliltus;Ergebnisse der diabetes-karte thüringen 2003: Ein projekt zur kontinuierlichen evaluierung und optimierung der behandlungs-qualität in der primären versorgung von patienten mit diabetes mellitus

Diabetes und Stoffwechsel

Volumn 13, Issue 6, 2004, Pages 287-294

  Sämann, Alexander ^a,b,c,d   Kaiser, Janina ^a,b,c   Seeliger, Sandra ^a,b,c   Müller, Ulrich Alfons ^a,b,c  

^a Funktionsbereich Endokrinol und S ^*  (Germany)

^b Klinik für Innere Medizin III   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Diabetes mellitus; HbA1c; Outcome quality

Indexed keywords

HEMOGLOBIN A1C;

ARTICLE; BLOOD PRESSURE MONITORING; DIABETES CONTROL; DIABETES MELLITUS; GENERAL PRACTICE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEALTH CARE QUALITY; HEALTH PROGRAM; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRIMARY HEALTH CARE; RURAL AREA; URBAN POPULATION;

EID: 9544235174     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Amos AF, McCarty DJ, Zimmer P: The rising global burden of Diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine 14 (1997) 7-85
2. Bagust A, Hopkinson PK, Maslove L, Currie CJ: The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. Diab Med 19 Suppl 4 (2002) 1-5
3. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance - the australien diabetes, obesity and lifestyle study. Diab Care 25 (2002) 829-834
4. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diab Care 22 (1998) 1414-1431
5. Abbott RD, Donahue RP, Kannel WB, Wilson PW: The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs. Women. The Framingham Study. JAMA 260 (1988) 3456-60, Erratum in: JAMA 7, 261(13) (1989) 1884
6. Abbott RD, Donahue RP, Kannel WB, Wilson PW: The Impact of Diabetes on Survival Following Myocardial Infarction in Men vs. Women. The Framingham Study. JAMA 260 (1988) 3456-60, Erratum in: JAMA 7, 261(13) (1989) 1884
7. Bertoni AG, Krop JS, Anderson GF, Brancati FL: Diabetes-related Morbidity and Mortality in a national Sample of US elders. Diab Care 25 (2002) 471-475
8. Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, Muggeo M: Diabetes Duration and Cause-Specific Mortality in the Verona Diabetes Study. Diab Care 23 (2000) 1119-1123
9. Ford ES, De Stefano F: Risk Factors for Mortality from All Causes and from Coronary Heart Disease among Persons with Diabetes. Findings from the National Health and Nutrition Examination Survey I. Epidemiologic Follow-up Study. Am J Epi 133 (1991) 1220-1230
10. Berger B, Stentstrom G, Sundkvist G: Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diab Care 22 (1999) 773-778
11. Gu K, Cowie CC, Harris M: Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971-1993. Diab Care 21 (1998) 1138-1145
12. Panzram G, Zabel-Langhennig R: Prognosis of diabetes mellitus in a geographically defined population. Diabetol 20 (1981) 587-591
13. DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 325 (2002) 746
14. Reichard P, Pihl M, Rosenqvist U, Sule J: Complications in IDDM are caused by elevated blood glucose levels: The Stockholm Diabetes Intervention Study (SIDS) at 10-year follow up. Diabetologia 39 (1996) 1483-1488
15. Berger M., Mühlhäuser I: Implementation of intensified insulin therapy. A european perspective. Diabet Med 12 (1995) 201-208
16. The Diabetes Control and Complication Trial Research Group (DCCT): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 6 (2002) 360 7-22
18. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
19. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
20. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 12, 317 (7160) (1998) 703-13, erratum in BMJ 2, 318 (1999) 29
21. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 12, 317 (7160) (1998) 703-13, erratum in BMJ 2, 318 (1999) 29
22. Liebl A: Diabetes und Blutzuckereinstellung. In: Deutsche Diabetes-Union (Hrsg.): Deutscher Gesundheitsbericht Diabetes. Kirchheim Mainz (2003)
23. Riehl J, Biermann E, Standl E: Insulinresistenz und Typ-2-Diabetes. Die IRIS-Studie. Diab Stoffw, 11 (2002) 150-158
24. Schulze J, Rothe U, Müller G, Kunath H, Fachkommission Diabetes Sachsen (2003) Verbesserung der Versorgung von Diabetikern durch das sächsische Betreuungsmodell. Dtsch Med Wochenschr 128 (2003) 1161-1168
25. Altenhofen L, Haß W, Oliveira J, Brenner G: Modernes Diabetesmanagement in der ambulanten Versorgung: Ergebnisse der wissenschaftlichen Begleitung der Diabetesvereinbarung in der KV Nordrhein. "Wissenschaftliche Reihe der KBV" Band 57. Köln: Dt. Ärzte-Verlag (2002)
26. 1c-Mapping zur Messung der Qualität der primären Versorgung von Patienten mit Diabetes mellitus in Thüringen. ZaeFQ 96 (2002) 615-620
27. Stede D für das Thüringer Landesamt für Statistik, Gruppe IV.3 (Bevölkerung). Freistaat Thüringen, Erfurt (2002)
28. 1c and severe Hypoglycemia after intensified treatment and education of 10000 type-1-diabetec patients. Results of a ten years nationwide quality-circle. Oral Lecture on the 37th Annual Meeting of the EASD, Glasgow 9.-13.9.2001. Diabetologia 44 (2001) Suppl 1 A16
29. SPSS ©. SPSS Inc., Chicago, Illinois, USA (2002)
30. Richtlinien der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriums-medizinischer Untersuchungen. Deutsches Ärzteblatt 2001; 98 (42): A2747 und Deutsches Ärzteblatt 99 (2002) A1187
31. Richtlinien der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriums-medizinischer Untersuchungen. Deutsches Ärzteblatt 2001; 98 (42): A2747 und Deutsches Ärzteblatt 99 (2002) A1187
32. Lyphochek Diabetes Control, Produkt-Begleitinformation: Bio-Rad Laboratories GmbH, München, BRD (2003)
33. The ALLHAT Collaborative Research Group: Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2003) 2981-97
34. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ 12, 317 (1998) 713-20
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2002) 145-153. Erratum in: N Engl J Med 342 (2000) 1376 and N Engl J Med 342 (2002) 748
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2002) 145-153. Erratum in: N Engl J Med 342 (2000) 1376 and N Engl J Med 342 (2002) 748
37. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2002) 145-153. Erratum in: N Engl J Med 342 (2000) 1376 and N Engl J Med 342 (2002) 748
38. The Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 19, 4 (1994) 1383-1389
39. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 16, 348 (1996) 1339-1342
40. Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, Giani G: High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia 46 (2003) 182-189
41. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany-results from the CODE-2 study: Exp Clin Endocrinol Diabetes 110 (2002) 10-16
42. Junghänel J, Netzer, Müller UA: Prävalenz Diabetischer Folgeerkrankungen als Qualitätsmerkmal der Diabetesbehandlung in der Hausarztpraxis in Thüringen und Mecklenburg-Vorpommern. Diab Stoffw 10, Suppl 1 (2001) 109
43. Müller UA, Junghänel J, Köhler S, Köhler M, Schumann M: Quality of diabetes care in a general practice network. Exp Clin Endocrinol Diabetes Suppl 1 (2000) S 163
44. Colman PG, Goodall GI, Garcia-Webb P, Williams PF, Dunlop ME: Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Australian Diabetes Society, the Royal College of Pathologists of Australia and the Australian Association of Clinical Biochemists [consensus development conference]. Med J Aust 167 (1997) 96-98
45. El-Agouza I, Abu Shahla A, Sirdah M: The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol 24 (2002) 285-289
46. 1c in type 1 diabetes mellitus. Pediatr Int 41 (1999) 357-362
47. Hoberman HD, Chido SM: Elevation of the Hemoglobin A1 Fraction in Alcoholism. Alcoholism Clinical and Experimental Research 6 (1982) 260-266
48. Fluckiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin Carbamylation in Uremia. N Engl J Med 304 (1981) 823-827